AcceXible Enters the Market in Colombia with Keralty

AcceXible makes the leap to Latin America. The Spanish company has entered the market in Colombia with Keralty to carry out clinical trials of its early detection tool for cognitive development, as explained by AcceXible’s CEO, Carla Zaldua.

The company, which specializes in developing a platform for the detection and monitoring of diseases through speech analysis, has already begun its international expansion in the second half of 2021, with a landing in the United Kingdom and the United States.

In May 2021, AcceXible closed a funding round of $873,000 (€800,000), carried out on the crowdfunding platform Crowdcube, and which involved investors from Spain, the UK, Germany, Italy, France, and Hong Kong. Two larger investors then took 5% of the company’s capital. Carla Zaldua and Javi Zaldua, both co-founders of AcceXible, remained as majority shareholders after the financing round.

Read more about AcceXible and find the latest business headlines with our companion app.Born2Invest mobile app makes it easy for you to keep informed, to intuitively move from story to story, and from section to section. Our clean design lets you read articles without clutter, and use the app with no limits on how many articles you can view.

AcceXible closed a funding round of $873,000 (€800,000) in May 2021

In addition to this round, since its inception in mid-2017, the company has received $873,000 (€800,000) more through the Neotec program, from the Center for Industrial Technological Development (Cdti), the Ministry of Economic Affairs and Digital Transformation, Enisa, and other partners.

In the coming months, the company will open a $2.2 million (€2 million) financing round with the aim of accelerating market entry and scaling its growth. The company is mainly looking for a large investment partner with expertise in the pharmaceutical or technology sector.

AcceXible expects to have a turnover of $491,000 (€450,000) in 2022. The company received CE marking on its product a year ago, allowing it to market its platform in the European Union. In Europe, only 20% of people suffering from dementia are diagnosed in the early stages. Its model enables early, non-invasive diagnosis and the possibility of monitoring the evolution of the disease remotely.

In Europe, only 20% of people suffering from dementia are diagnosed in the early stages

Recently, the company has renewed the agreement with Quirónsalud and the Ace Foundation to continue testing its tools in the centers of this hospital group in Spain. Abroad, AcceXible has signed collaborations with Southwestern University (Texas) and another with the British National Health System (NHS).

The company has a team of nine people and is headquartered in Barcelona at Pier01, Tech Barcelona, as well as offices in Bilbao. In the Basque city, AcceXible is located in Innolab, an open innovation center that combines start-ups, SMEs, corporations, universities, and technology centers.

__

(Featured image by bergslay via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.